Randomized phase I/II Pilot study of the immunogenicity of cyclophosphamide with peptide pulsed mature dendritic cells for patients with previously treated ovarian epithelial or primary peritoneal carcinoma

Trial Profile

Randomized phase I/II Pilot study of the immunogenicity of cyclophosphamide with peptide pulsed mature dendritic cells for patients with previously treated ovarian epithelial or primary peritoneal carcinoma

Completed
Phase of Trial: Phase I/II

Latest Information Update: 19 Apr 2017

At a glance

  • Drugs Dendritic cell vaccines (Primary) ; Cyclophosphamide; Pneumococcal vaccine
  • Indications Ovarian cancer; Peritoneal cancer
  • Focus Pharmacodynamics; Therapeutic Use
  • Acronyms DC-Ova
  • Most Recent Events

    • 26 Jan 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 26 Jan 2009 Actual end date (Aug 2008) added as reported by ClinicalTrials.gov.
    • 05 May 2008 Status changed from recruiting to in progress, reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top